STOCK TITAN
  1. Home
  2. Sec-filings
  3. AXGN
  4. [Form 4] Axogen, Inc. Insider Trading Activity

AXGN Form 4: Director Kathy Weiler Receives 14,150-Share RSU Grant

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Axogen, Inc. (AXGN) filed a Form 4 disclosing that Director Kathy Johnson Weiler received an annual equity grant of 14,150 restricted stock units (RSUs) on 06/19/2025. Each RSU converts into one share of common stock upon vesting, giving Weiler contingent rights to the same number of shares.

The grant is valued at approximately $150,000 based on Axogen’s share price at the grant date and vests in full on 06/19/2026, the one-year anniversary of the award. Following the transaction, the director beneficially owns 14,150 AXGN shares, all held directly. No shares were sold or otherwise disposed of.

The filing reflects routine board compensation, introduces no immediate cash outflow for the company, and does not materially change Axogen’s share count or insider ownership profile.

Positive

  • None.

Negative

  • None.

Insights

TL;DR – Routine RSU grant to director; neutral valuation impact; no buy/sell activity; signals standard board retention.

The 14,150-share RSU award to Director Weiler equates to roughly $150 k, consistent with Axogen’s historical board compensation. Because shares vest after one year and carry a $0 exercise price, dilution is minimal and already included in the company’s equity-based compensation plans. No open-market transactions occurred, so there is no immediate liquidity signal for investors. Overall, the event is ordinary-course and unlikely to influence AXGN’s near-term trading dynamics.

Insider Weiler Kathy Johnson
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Units 14,150 $0.00 --
Holdings After Transaction: Restricted Stock Units — 14,150 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Weiler Kathy Johnson
(Last) (First) (Middle)
C/O AXOGEN, INC. 13631 PROGRESS BLVD.,
SUITE 400
(Street)
ALACHUA FL 32615
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/19/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 06/19/2025 A 14,150 (2) (2) Common Stock 14,150 $0 14,150 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
2. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.
Remarks:
/s/ Marc Began, as attorney-in-fact for Kathy Weiler 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many shares did Director Kathy Weiler receive in the 2025 Form 4 for AXGN?

She was granted 14,150 restricted stock units, each convertible into one share of Axogen common stock.

What type of security was reported in Axogen’s latest Form 4 filing?

The filing reports an award of restricted stock units (RSUs) to the director.

When will the 14,150 RSUs awarded on 06/19/2025 vest?

The RSUs vest on 06/19/2026, exactly one year after the grant date.

What is the stated value of the equity grant to Director Weiler?

The company valued the grant at approximately $150,000 on the grant date.

Did the Form 4 disclose any share sales or disposals by the director?

No. The filing shows only an acquisition via RSU grant; there were no dispositions.